Merck & Co. Inc. (MRK)

79.43
0.19 0.24
NYSE : Health Technology
Prev Close 79.24
Open 79.00
Day Low/High 78.81 / 79.54
52 Wk Low/High 52.83 / 80.19
Volume 7.79M
Avg Volume 12.47M
Exchange NYSE
Shares Outstanding 2.60B
Market Cap 207.54B
P/E Ratio 63.85
Div & Yield 2.20 (2.49%)
Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For Treatment Of Refractory Or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For Treatment Of Refractory Or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Latest Reasons to Avoid Alzheimer's Plays

Latest Reasons to Avoid Alzheimer's Plays

Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #8 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #91 spot out of 500.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AINV, CRNT, JCAP, MRK, ODC Downgrades: FRPH, SSY, UHS Initiations: JE Read on to get TheStreet Quant Ratings' detailed report:

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

I continue to see these names as bargains in the biotech and biopharma space.

Small Cap Biotech Bargains

Small Cap Biotech Bargains

Here are 2 small caps I continue to see as bargains in this space.

Sanofi, Merck and J&J Tout Lower Drug Prices

Sanofi, Merck and J&J Tout Lower Drug Prices

While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.

Jim Cramer: Tech Can't Do it All Alone

Jim Cramer: Tech Can't Do it All Alone

Tech and retail gains aren't enough to lead markets to new highs.

IQiyi, the Netflix of China, Marches Higher; Apple's WWDC, Fiat and More--ICYMI

IQiyi, the Netflix of China, Marches Higher; Apple's WWDC, Fiat and More--ICYMI

Here's what you need to know for Monday, June 4.

LYNPARZA® (olaparib) In Combination With Abiraterone Delayed Disease Progression In Metastatic Castration-Resistant Prostate Cancer

LYNPARZA® (olaparib) In Combination With Abiraterone Delayed Disease Progression In Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data which showed clinical improvement in median radiologic progression-free survival (rPFS) with LYNPARZA ® (olaparib) in combination with abiraterone...

Dow Gains 178 Points; Nasdaq Jumps to New Record

Dow Gains 178 Points; Nasdaq Jumps to New Record

Stocks rise on Monday as stronger-than-expected jobs data from the U.S. overshadows trade fears.

Merck Higher on Lung Cancer Data

Merck Higher on Lung Cancer Data

The drugmaker's presentations at ASCO's annual meeting included data on Keynote-407, which Credit Suisse analyst Vamil Divan described as a 'clear positive.'

Merck's KEYTRUDA® (pembrolizumab) Showed Promising Anti-Tumor Activity In Patients With Advanced Small Cell Lung Cancer (SCLC) In Phase 2 KEYNOTE-158 Study

Merck's KEYTRUDA® (pembrolizumab) Showed Promising Anti-Tumor Activity In Patients With Advanced Small Cell Lung Cancer (SCLC) In Phase 2 KEYNOTE-158 Study

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced interim data from a cohort of the Phase 2 KEYNOTE-158 study evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy in patients with previously treated advanced...

Merck's KEYTRUDA® (pembrolizumab) Demonstrated Long-Term Survival Benefit Based On Four And Five Years Of Follow-Up From Two Pivotal Studies In Advanced Melanoma

Merck's KEYTRUDA® (pembrolizumab) Demonstrated Long-Term Survival Benefit Based On Four And Five Years Of Follow-Up From Two Pivotal Studies In Advanced Melanoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced long-term efficacy data from the Phase 3 KEYNOTE-006 study and the melanoma cohort of the Phase 1b KEYNOTE-001 study investigating KEYTRUDA, Merck's anti-PD-1 therapy, in...

Merck's KEYTRUDA® (pembrolizumab) Showed Overall Response Rate Of Nearly 40 Percent As First-Line Therapy In Patients With Advanced Clear Cell Renal Cell Carcinoma (RCC) In Phase 2 KEYNOTE-427 Study

Merck's KEYTRUDA® (pembrolizumab) Showed Overall Response Rate Of Nearly 40 Percent As First-Line Therapy In Patients With Advanced Clear Cell Renal Cell Carcinoma (RCC) In Phase 2 KEYNOTE-427 Study

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as first-line treatment for advanced clear cell renal cell...

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival In First-Line Treatment Of Metastatic Squamous Non-Small Cell Lung Cancer In Phase 3 KEYNOTE-407 Study

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival In First-Line Treatment Of Metastatic Squamous Non-Small Cell Lung Cancer In Phase 3 KEYNOTE-407 Study

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from KEYNOTE-407, a pivotal, Phase 3 study evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel, as...

Income Seeker: Verizon's 5% Yield Is No Mere Dog of the Dow

The telecom giant is the highest-yielding stock among the Dow industrials.

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival And Progression-Free Survival As First-Line Treatment For Squamous Non-Small Cell Lung Cancer (NSCLC) In Pivotal Phase 3 KEYNOTE-407 Trial

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival And Progression-Free Survival As First-Line Treatment For Squamous Non-Small Cell Lung Cancer (NSCLC) In Pivotal Phase 3 KEYNOTE-407 Trial

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-407 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel, as first-line...

Merck Announces Third-Quarter 2018 Dividend

Merck Announces Third-Quarter 2018 Dividend

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

These names are moving up or down in a big way ahead of releasing drug-trial results.

New Data From Merck's Leading Immuno-Oncology Clinical Development Program In Over 25 Tumor Types To Be Presented At 2018 ASCO Annual Meeting

New Data From Merck's Leading Immuno-Oncology Clinical Development Program In Over 25 Tumor Types To Be Presented At 2018 ASCO Annual Meeting

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new combination and monotherapy data from Merck's oncology portfolio, anchored by anti-PD-1 therapy KEYTRUDA, will be presented at the 54 th Annual Meeting of...

4 Names to Buy in a Refreshed Biotech Space

4 Names to Buy in a Refreshed Biotech Space

After a strong week for the biotech sector, these names have potential catalysts to move shares.

Healthcare Stocks Rebound After President Trump's Speech on Drug Pricing

Healthcare Stocks Rebound After President Trump's Speech on Drug Pricing

President Trump delivered a highly-anticipated speech on lowering the cost of drugs for Americans on Friday afternoon.

LYNPARZA® (olaparib) Tablets Receive EU Approval For The Treatment Of Platinum-Sensitive Relapsed Ovarian Cancer

LYNPARZA® (olaparib) Tablets Receive EU Approval For The Treatment Of Platinum-Sensitive Relapsed Ovarian Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency (EMA) has approved LYNPARZA ® (olaparib) tablets (300 mg twice daily) for use as a maintenance therapy for patients...

TheStreet Quant Rating: A+ (Buy)